Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction.
IBD clinical
inflammatory bowel disease
infliximab
Journal
Frontline gastroenterology
ISSN: 2041-4137
Titre abrégé: Frontline Gastroenterol
Pays: England
ID NLM: 101528589
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
24
09
2019
revised:
12
11
2019
accepted:
22
11
2019
entrez:
26
10
2020
pubmed:
27
10
2020
medline:
27
10
2020
Statut:
epublish
Résumé
Accelerated dose infliximab (IFX) induction is associated with reduced short-term colectomy rate in acute severe ulcerative colitis (ASUC). Data on medium/long-term outcomes of this strategy are limited. Evaluate medium/long-term outcomes in patients receiving IFX induction for ASUC, comparing accelerated dose (AD) and standard dose (SD) induction. Retrospective study of consecutive patients admitted with corticosteroid-refractory ASUC in four tertiary referral centres within INITIative IBD research network (www.initiativeibd.ie). IFX rescue was given either as SD (weeks 0, 2, 6) or AD (<28 days) from January 2010 to September 2017. AD induction has been utilised in participating centres since 2014. Consequently SD patients were subdivided based on time period of IFX rescue: historical SD group (SD1) (2010-2013) and current SD group (SD2) (2014-2017). Primary endpoint was time to colectomy; secondary endpoint was time to IFX discontinuation if induction was complete. 145 patients received rescue IFX (AD=58, SD Time to colectomy is significantly prolonged with use of AD IFX in selected ASUC patients with more severe disease. Historical use of standard IFX induction for all ASUC patients is associated with inferior long-term outcomes.
Identifiants
pubmed: 33104766
doi: 10.1136/flgastro-2019-101335
pii: flgastro-2019-101335
pmc: PMC7569515
doi:
Types de publication
Journal Article
Langues
eng
Pagination
441-447Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Gut. 1996 Jun;38(6):905-10
pubmed: 8984031
J Clin Gastroenterol. 2018 Jul;52(6):e48-e52
pubmed: 28737646
Gut. 2019 Dec;68(Suppl 3):s1-s106
pubmed: 31562236
Gut. 2018 Feb;67(2):237-243
pubmed: 28053054
Gastroenterology. 2015 Aug;149(2):350-5.e2
pubmed: 25917786
J Crohns Colitis. 2018 Feb 28;12(3):289-297
pubmed: 29121178
Gastroenterology. 2005 Jun;128(7):1805-11
pubmed: 15940615
Clin Gastroenterol Hepatol. 2015 Feb;13(2):330-335.e1
pubmed: 25086187
Aliment Pharmacol Ther. 2013 Aug;38(4):377-87
pubmed: 23799948
Clin Gastroenterol Hepatol. 2015 Feb;13(2):336-8
pubmed: 25285408
Clin Gastroenterol Hepatol. 2019 Feb;17(3):502-509.e1
pubmed: 29944926
N Engl J Med. 2005 Dec 8;353(23):2462-76
pubmed: 16339095
Aliment Pharmacol Ther. 2019 Sep;50(6):675-683
pubmed: 31456297
J Crohns Colitis. 2018 May 25;12(6):662-669
pubmed: 29659758